Non-Proliferative Diabetic Retinopathy
Ophthalmology
Prevalence
2800.0 / 100K
Incidence
350.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| AXPAXLI | OCULAR THERAPEUTIX, INC (OCUL) |
Frequently asked questions
How many drugs are in development for Non-Proliferative Diabetic Retinopathy?
BioSniper tracks 1 drug in development for Non-Proliferative Diabetic Retinopathy across 1 company.
How many clinical trials target Non-Proliferative Diabetic Retinopathy?
There are 1 clinical trial targeting Non-Proliferative Diabetic Retinopathy tracked by BioSniper.
What is the prevalence of Non-Proliferative Diabetic Retinopathy?
The estimated prevalence of Non-Proliferative Diabetic Retinopathy is approximately 2800.0 per 100,000 population.
Deep-dive into Non-Proliferative Diabetic Retinopathy
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis